TSH suppression attenuates the early efficacy of zoledronic acid in osteoporosis - PubMed
6 hours ago
- #osteoporosis
- #zoledronic acid
- #TSH suppression
- TSH suppression therapy reduces the early effectiveness of zoledronic acid in osteoporosis patients.
- The study involved two groups: osteoporosis patients with TSH suppression (TSH + OP) and without (TSH - OP).
- Both groups received zoledronic acid, calcium, and calcitriol, but the TSH + OP group showed less BMD improvement.
- At 9 months, significant differences in BMD changes were observed at the lumbar spine, left hip, and femoral neck.
- Bone turnover markers (PINP and β-CTX) remained higher in the TSH + OP group at all time points.
- Subgroup analyses indicated the attenuation was more pronounced in postmenopausal women.
- Serum PINP and β-CTX are useful biomarkers for monitoring patients undergoing TSH suppression therapy.